This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout

References
Foster, R.N. Innovation: The Attacker's Advantage (Summit Books, New York; 1986).
Christensen, C.M. & Raynor, M.E. The Innovator's Solution: Creating and Sustaining Successful Growth (Harvard Business School Press, Boston; 2003).
McNamee, L.M. & Ledley, F.D. Nat. Biotechnol. 30, 937–943 (2012).
DiMasi, J.A., Feldman, L., Seckler, A. & Wilson, A. Clin. Pharmacol. Ther. 87, 272–277 (2010).
Gschwind, A., Fischer, O.M. & Ullrich, A. Nat. Rev. Cancer 4, 361–370 (2004).
Sheridan, C. Nat. Biotechnol. 29, 121–128 (2011).
Cockburn, I.H.R. Proc. Natl. Acad. Sci. USA 93, 12725–12730 (1996).
Pisano, G.P. Science Business: the Promise, the Reality, and the Future of Biotech (Harvard Business School Press, Boston; 2006).
Guedj, I. & Scharfstein, D. Organizational Scope and Investment: Evidence from the Drug Development Strategies of Biopharmaceutical Firms. NBER working paper 10933 (National Bureau of Economic Research, 2004).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
McNamee, L., Ledley, F. Making the biotech IPO work. Nat Biotechnol 31, 969–970 (2013). https://doi.org/10.1038/nbt.2711
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2711
This article is cited by
-
What does the current biotech stock market value?
Nature Biotechnology (2015)
-
Why commercialization of gene therapy stalled; examining the life cycles of gene therapy technologies
Gene Therapy (2014)